The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
FTIR and machine learning-based technology enables real-time, cost-effective quantification of food adulterants
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
Former Cipla MD & CEO to lead next phase of growth at science-led CDMO platform; Vivek Sharma transitions to advisory role
New minimally invasive biomarker test enables earlier diagnosis and improved clinical decision-making, aligned with global guidelines
The deal signals a clear push to expand access to care in underserved regions
The agreements aim to strengthen medicine quality, patient safety and pharmaceutical research in India
Subscribe To Our Newsletter & Stay Updated
